Table 2.
Clinical Characteristics of the Study Participants.
| Parameter | Normoglycemia (n = 17) | Prediabetes (n = 28) | p-value |
|---|---|---|---|
| Age (years) | 59.1 ± 9.0 | 61.1 ± 7.7 | 0.424 |
| Gender (% female) | 64.7 | 71.4 | 0.637 |
| BMI (kg/m²) | 24.3 ± 2.6 | 24.5 ± 3.9 | 0.876 |
| SBP (mmHg) | 126.5 ± 14.5 | 132.9 ± 12.2 | 0.124 |
| DBP (mmHg) | 80.4 ± 9.4 | 76.9 ± 10.3 | 0.261 |
| FPG (mg/dl) | 90.2 ± 6.3 | 102.1 ± 10.7 | <0.0001 |
| HbA1c (%) | – | 5.9 ± 0.5 | – |
| Triglyceride (mg/dl) | 95.6 ± 61.2 | 119.1 ± 94.2 | 0.367 |
| LDL-C* (mg/dl) | 112.5 ± 42.9 | 100.9 ± 28.6 | 0.282 |
| HDL-C# (mg/dl) | 62.7 ± 31.4 | 60.5 ± 14.7 | 0.751 |
| IFG duration (years) | – | 3.4 ± 2.8 | – |
| Drugs (% use) | |||
| * ACEI or ARB** | 23.5 | 48.1 | 0.102 |
| * DHP-CCB## | 58.8 | 37.0 | 0.158 |
| * Thiazide-like diuretic | 11.8 | 25.9 | 0.257 |
| * Statins | 52.9 | 57.1 | 0.783 |
| * Fibrate | 11.8 | 10.7 | 0.913 |
| eGFR (ml/min) | 76.4 ± 26.7 | 84.7 ± 21.9 | 0.264 |
| FRAX: 10-year risk of hip fractures (%) (FRAX-H) | 0.7 ± 1.0 | 1.5 ± 2.1 | 0.215 |
| FRAX:10-year risk of osteoporotic fractures (%) (FRAX-O) | 2.9 ± 1.6 | 4.6 ± 3.5 | 0.085 |
*LDL-C, low-density lipoprotein cholesterol.
#HDL-C, high-density lipoprotein cholesterol.
**ACEI angiotensin-converting enzyme inhibitors.
**ARB, angiotensin II receptor blockers.
##DHP-CCB, dihydropyridine calcium channel blockers.